https://www.oncologynurseadvisor.com Tue, 28 Nov 2023 16:01:15 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/acute-leukemia-target-therapy-next-generation-sequence-assays-risk/ Tue, 28 Nov 2023 15:50:00 +0000 https://www.oncologynurseadvisor.com/?p=114420 Researchers sought to assess the future landscape of treatments and cures for childhood ALL.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/follicular-lymphoma-copanlisib-patients-benefit-durable-survival-treatment/ Wed, 14 Jun 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=108550 Researchers sought to determine whether copanlisib would have a response in patients with relapsed/refractory indolent follicular lymphoma.]]> https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/leukemia-cll-ibrutinib-obinutuzumab-venetoclax-not-improve-survival-pfs/ Tue, 13 Jun 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=108540 Researchers investigated whether adding venetoclax to ibrutinib and obinutuzumab would improve survival and allow for discontinuation of treatment in older patients with CLL.]]> https://www.oncologynurseadvisor.com/home/cancer-types/hematologic-cancers/chronic-leukemia-guidelines-real-world-treatment-risk-not-followed/ Tue, 28 Jun 2022 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=100256 “Excellent” overall survival is achievable with currently available drugs, according to researchers.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/malt-lymphoma-predicting-disease-progression-treatment-risk/ Fri, 24 Jun 2022 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=100254 The researchers examined the prognostic significance of AMC and LMR in 316 patients with MALT lymphoma.]]> https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/american-society-of-clinical-oncology-asco/asco-2022/breast-cancer-trastuzumab-deruxtecan-practice-changing-treatment/ Mon, 13 Jun 2022 14:45:00 +0000 https://www.oncologynurseadvisor.com/?p=99933 Trastuzumab deruxtecan improved progression-free and overall survival, compared with physician’s choice of therapy.]]> https://www.oncologynurseadvisor.com/home/cancer-types/breast-cancer/invasive-breast-cancer-digital-breast-tomosynthesis-superior-detection/ Tue, 26 Apr 2022 14:15:00 +0000 https://www.oncologynurseadvisor.com/?p=98582 The detection rate was 48% higher with digital breast tomosynthesis.]]> https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/covid19-cancer-type-risk-breakthrough-varies-vaccine-patients/ Mon, 18 Apr 2022 14:30:00 +0000 https://www.oncologynurseadvisor.com/?p=98428 The risk of breakthrough SARS-CoV-2 infections was highest for liver cancer and lowest for thyroid cancer.]]> https://www.oncologynurseadvisor.com/home/oncology-nursing/pandemic-nursing-related-effects-treatment-risk-what-lies-ahead/ Fri, 04 Feb 2022 18:50:38 +0000 https://www.oncologynurseadvisor.com/?p=97184 A nationwide survey showed stress and discontentment among nurses in general, as well as oncology nurses, may have a crippling effect on the US healthcare system.]]> https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/ash-2021/hodgkin-lymphoma-geriatric-assessment-chronologic-age-measure-qol/ Mon, 20 Dec 2021 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=96547 A prospective study sought to determine the value of geriatric assessment in patients with non-Hodgkin lymphoma, compared with assessment based on chronological age.]]>